Key Developments: Cardiovascular Systems Inc (CSII.O)

CSII.O on Nasdaq

27.73USD
7 Jul 2015
Change (% chg)

$0.78 (+2.89%)
Prev Close
$26.95
Open
$26.99
Day's High
$27.83
Day's Low
$26.56
Volume
307,745
Avg. Vol
329,684
52-wk High
$41.28
52-wk Low
$23.15

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cardiovascular Systems Inc gives Q4 2015 earnings guidance; revenue guidance below analysts' estimates
Wednesday, 29 Apr 2015 04:00pm EDT 

Cardiovascular Systems Inc:Anticipates Q4 2015 revenue growth of 24 percent to 28 percent over Q4 2014, to a range of $49.0 million to $50.5 million.Anticipates Q4 2015 Net loss in the range of $(9.0) million to $(10.0) million, or loss per common share ranging from $(0.28) to $(0.31).Q4 2015 revenue of $50.7 million, net income of $(9.0) million and EPS of $(0.29) - Thomson Reuters I/B/E/S.  Full Article

Cardiovascular Systems receives FDA clearance for New Peripheral Diamondback Device
Monday, 20 Apr 2015 07:00am EDT 

Cardiovascular Systems Inc:Received FDA clearance for the new 4 French (4 Fr) 1.25 Solid Diamondback 360 Peripheral Orbital Atherectomy System (OAS) for the treatment of peripheral artery disease (PAD).Specifically, the clearance covers the company's 145cm long.New 1.25mm Diamondback 360 Solid Crown, 4 Fr sheath compatible; and.Modified 1.25mm Diamondback 360 Micro Crown, 4 Fr sheath compatible.  Full Article

Cardiovascular Systems Inc gives Q3 2015 outlook in line with analysts' estimates
Wednesday, 28 Jan 2015 04:00pm EST 

Cardiovascular Systems Inc:Anticipates Q3 2015 revenue to a range of $46.0 million to $47.7 million.Anticipates Q3 2015 Net loss in the range of $(10.0) million to $(11.0) million, or loss per common share ranging from $(0.32) to $(0.35).Q3 2015 revenue of $46.2 mln, net income of $(10.0) mln and EPS of $(0.33) - Thomson Reuters I/B/E/S.  Full Article

Cardiovascular Systems receives CE mark for Stealth 360 peripheral orbital atherectomy system
Monday, 3 Nov 2014 10:45am EST 

Cardiovascular Systems Inc:Announced that it has received CE (ConformitĂ© EuropĂ©enne) Mark for its Stealth 360 Orbital Atherectomy System.Stealth 360 is a percutaneous OAS that is indicated to treat patients who suffer from peripheral arterial disease (PAD).  Full Article

Cardiovascular Systems Inc gives Q2 2015 outlook, earnings outlook below analysts' estimates
Wednesday, 29 Oct 2014 04:00pm EDT 

Cardiovascular Systems Inc:Expects Q2 2015 revenue growth of 33 - 39 pct over Q2 2014, to a range of $43.1 - $44.8 million.Q2 2015 gross profit as a percentage of revenues similar to Q1 2015.Q2 2015 net loss in the range of $(11.0) - $(12.0) million.Q2 2015 loss per common share ranging from $(0.35) to $(0.38), assuming 31.5 million average shares outstanding.Q2 2015 revenue of $43.2 mln, net income of $(8.88) mln, EPS of $(0.28) - Thomson Reuters I/B/E/S.  Full Article

Cardiovascular Systems Inc's Board Chair to retire
Wednesday, 17 Sep 2014 05:00pm EDT 

Cardiovascular Systems Inc:Says its chairman of the board, Glen D. Nelson, M.D., 77, plans to retire and will not stand for re-election at company's 2014 annual meeting of shareholders on Nov. 12, when his term ends.Scott R. Ward, a CSI director since 2013, will be named chairman.  Full Article

Cardiovascular Systems Inc gives Q1 2015 mixed outlook
Wednesday, 6 Aug 2014 04:01pm EDT 

Cardiovascular Systems Inc:Expects Q1 2015 revenue to a range of $39.5 - $40.7 mln.Expects Q1 2015 net loss in the range of $(10.3) -$(11.0) mln, or loss per common share ranging from $(0.33) to $(0.35).Q1 2015 revenue of $38.9 mln, net income of $(8.24) mln, EPS of $(0.25) - Thomson Reuters I/B/E/S.  Full Article

Cardiovascular Systems Inc gives Q4 2014 guidance, earnings guidance above analysts' estimates
Wednesday, 30 Apr 2014 04:00pm EDT 

Cardiovascular Systems Inc:Sees Q4 2014 revenue growth of 26 to 31 pct over the Q4 2013, to a range of $36.3 to $37.8 million.Net loss in the range of $(8.4) to $(9.3) million, or loss per common share ranging from $(0.27) to $(0.30).Q4 2014 revenue of $36.5 mln, net income of $(9.8) mln and EPS of $(0.32) - Thomson Reuters I/B/E/S.  Full Article

Cardiovascular Systems Inc receives FDA clearance for low profile, 60cm diamondback devices designed to expand the treatment of peripheral artery disease
Monday, 10 Mar 2014 08:00am EDT 

Cardiovascular Systems Inc:Says it has received FDA clearance of its new Diamondback 360((reg))60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD).CSI's new Diamondback Peripheral 60cm systems are available in two crown designs, the 1.25mm Micro Crown, and the 1.25mm Solid Crown.  Full Article

Cardiovascular Systems Inc gives Q3 2014 mixed guidance
Wednesday, 29 Jan 2014 04:00pm EST 

Cardiovascular Systems Inc:Expects Q3 2014 revenue growth of 25 percent to 30 percent over the third quarter of 2013, to a range of $33.0 million to $34.5 million.Expects Q3 2014 net loss in the range of $(9.2) million to $(10.1) million, or loss per common share ranging from $(0.31) to $(0.34).Q3 2014 revenue of $32.7 million, net income of $(7.1) million and EPS of $(0.28) - Thomson Reuters I/B/E/S.  Full Article

Search Stocks